Short telomeres are major drivers of disease and aging

TERT mRNA extends telomeres

Recent Advances Toward Clinical Trials


Benefitting from our TERT mRNA telomere extension platform technology, Rejuvenation’s pipeline encompasses multiple organ systems as well as cell therapies.  These programs target fatal diseases with high unmet medical need.



ramunas - circle - 500x500px

John Ramunas

Founder & CEO, Stanford PhD, Co-inventor, Decade of experience with mRNA for therapeutic applications. Thesis title: Telomere extension to extend human healthspan.

glenn circle - 500 px

Glenn Markov

Founder & COO, Stanford PhD, Decade of experience in genetics and epigenetics of cellular reprogramming.

Bo Yang

Bo Yang

Research Fellow, MD, MSc, PhD, CTBS, Clinical and Preclinical Development at Boehringer Ingelheim and Gilead.  Postdoc at Yale University on novel roles of ion transport proteins.


Kyle Brewer

Research Scientist, Postdoc at Stanford University on the proteomics of aging in the liver and brain, PhD in Biophysics at UT Southwestern on neurotransmitter release. 


Helen M. Blau

Founder & Advisor, Co-inventor, Professor at Stanford University, discovered that short telomeres underlie the fatal etiology of multiple monogenic diseases.

Apoorva Shankar

Apoorva Shankar

Life Science Research Associate, MSc in Biotechnology.

Jordan Spice


Bioengineering Research Associate, BSc in Bioengineering

Tanya Velasco


Life Science Research Assistant, BSc in Biology


Robin E. Holbrook

Director of Finance and Administration, Stanford AB in Cultural Anthropology,  30+ years of F&A experience supporting research excellence at Stanford School of Medicine.

Contact Us


Employment inquiries: 

Investor inquiries:

General inquiries: 

Extending Telomeres
to Extend the Healthspan

At Rejuvenation we're using mRNA to treat fatal diseases of aging